Affimed Nv

AFMD

1.40

0.00

0.0%

Please Login or Register

Login|Register FREE

Stock Price
Open: 1.40
Prev. Close: 1.40
Low/Hi: 1.35 - 1.40
52-Week: 1.15 - 2.95
Volumes
Equity: 44,430
90-Day Avg: 331,533
Option: 4
90-Day Avg: 114
Volatility
Todays Stock Vol: 57.7
20-Day (HV): 88.3
52-Week (HV): 79.8
30-Day IV: 81.7 -1.5
IV Pct Rank: 54% Moderate
Fundamental
Div. Yield:
Earnings: 29-Mar (Est.)
P/E Ratio:
Market Cap: 62.5 M
Short Int Pct: 0.0%
Pct Held By Inst.: 65.3%
Stock Info
Type: Common
Sector: Healthcare
Industry: Biotechnology

AFMD Company Events

Upcoming Events
Event Event Date Location Info
No Upcoming Events
Past Events
Event Event Date Location Info
59th American Society of Hematology (ASH) Annual Meeting and Exposition 2017 Dec 11, 2017
59thAmerican Society of Hematology (ASH) Annual Meeting Dec 9, 2017 - Dec 10, 2017
Jefferies 2017 London Healthcare Conference Nov 15, 2017
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology Sep 28, 2:30 PM
2017 Wells Fargo Healthcare Conference Sep 7, 9:25 AM
EACR-AACR-SIC Special Conference 2017 Jun 24, 2017 - Jun 27, 2017
Annual General Meeting of Shareholders Jun 20, 2017
Jefferies 2017 Global Healthcare Conference Jun 6, 2:00 PM
American Society of Clinical Oncology (ASCO) 2017 Annual Meeting Jun 2, 2017 - Jun 6, 2017
AACR Annual Meeting 2017 Apr 1, 2017 - Apr 5, 2017
Oppenheimer 27th Annual Healthcare Conference Mar 21, 4:30 AM
Cowen and Company 37th Annual Health Care Conference Mar 7, 10:40 AM
Leerink Partners 6th Annual Global Healthcare Conference Feb 15, 2017
58thAmerican Society of Hematology (ASH) Annual Meeting Dec 3, 2016 - Dec 5, 2016 San Diego, California
Jefferies 2016 London Healthcare Conference Nov 16, 2016 London
i

Dr. Adi Hoess, CEO, will present.

Credit Suisse 25th Annual Healthcare Conference Nov 7, 12:30 PM
i

Dr. Florian Fischer, CFO, will present

Leerink Partners Roundtable Series Sep 29, 2016 New York
Leerink Partners Rare Disease & IO Roundtable Series Sep 29, 1:30 PM
2016 Wells Fargo Healthcare Conference Sep 8, 2016 Boston, MA
Credit Suisse Antibody Sep 7, 2016 New York, NY
Annual General Meeting of Shareholders Jun 21, 2016 Hilton Amsterdam, Apollolaan 138, 1077 BG Amsterdam, The Netherlands
Annual General Meeting o Jun 21, 2016 Amsterdam, The Netherlands.
Jefferies 2016 Healthcare Conference Jun 7, 2016 New York City
i

Dr. Adi Hoess, CEO, will present

UBS Global Healthcare Conference May 23, 1:00 PM
UBS Global Healthcare Conference May 23, 2016 - May 25, 2016 New York
i

Dr. Adi Hoess, CEO, will present

UBS Global Healthcare Conference May 23, 2016 New York
i

Dr. Adi Hoess, CEO, will present

AACR Annual Meeting 2016 Apr 16, 2016 - Apr 20, 2016 New Orleans, LA.
i

biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that preclinical data from a combination study of Affimed's lead candidate AFM13 and checkpoint modulators, including checkpoint inhibitor PD-1, as well as data on Affimed's preclinical programs AFM21/22 and AFM24 will be presented

Cowen Health Care Conference Mar 7, 2016
Symposium on Emerging Approaches in Cancer Immunotherapy Feb 22, 2016
i

CMO, Jens-Peter Marschner, will present

Leerink Partners 5th Annual Global Healthcare Conference Feb 11, 11:10 AM New York City
i

Dr. Adi Hoess, CEO, will present

Host Hodgkin's Lymphoma Day with Key Opinion Leaders Jan 26, 2016 New York City.
i

The discussion will be moderated by Affimed's Chief Medical Officer, Jens-Peter Marschner, M.D., and the Company's Chief Scientific Officer, Martin Treder, Ph.D., will also be available to discuss AFM13, the Company's lead candidate currently in a Phase 2a study for the treatment of Hodgkin's lymphoma.

Hodgkin's Lymphoma Day Jan 26, 2016 New York City
i

The discussion will be moderated by Affimed's Chief Medical Officer, Jens-Peter Marschner, M.D., and the Company's Chief Scientific Officer, Martin Treder, Ph.D., will also be available to discuss AFM13, the Company's lead candidate currently in a Phase 2a study for the treatment of Hodgkin's lymphoma

Oppenheimer 26th Annual Healthcare Conference Dec 8, 3:20 PM - Dec 9, 2015 New York
i

Dr. Adi Hoess, CEO, will present

57th annual American Society of Hematology (ASH) conference Dec 5, 2015 - Dec 8, 2015 Orlando, Florida.
i

two of the Company's abstracts have been chosen for poster presentations

Jefferies 2015 Global Healthcare Conference Nov 18, 2015 - Nov 19, 2015 London
i

Dr. Adi Hoess, CEO, will present

30th annual Society for Immunotherapy of Cancer (SITC) conference Nov 4, 2015 National Harbor, Maryland
Leerink Partners Inaugural Immuno-Oncology Roundtable Conference Oct 1, 2015 New York City
i

Dr. Adi Hoess, CEO, will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference

General Meeting of Shareholders Jun 9, 2015
American Society of Clinical Oncology (ASCO) 2015 Annual Meeting May 29, 2015
i

The results of this preclinical study developed by Dr. Holbrook Kohrt at Stanford University and using PDX mice with actual human cancers, demonstrate the impressive synergy of Affimed's AFM13 in combination with PD-1. These findings, along with AFM13's proven safety profile in patients, support the further investigation of AFM13 as a combination therapy with check-point-inhibiting antibodies to treat various hematologic malignancies expressing CD30

UBS Global Healthcare Conference - New York May 19, 10:30 AM

Wait, Before You Leave...

Want to Know More About AFMD Earnings?

Receive your FREE email to get Wall Street expected earnings moves and daily upcoming earnings alerts!
Market Chameleon